Database Query Results : , , S6K

S6K, S6 kinase: Click to Expand ⟱
Source:
Type: protein
S6K (S6 kinase) is a protein that plays a crucial role in cell growth, proliferation, and survival. It is a downstream target of the mTOR (mechanistic target of rapamycin) signaling pathway, which is a central regulator of cellular metabolism, growth, and division.

Research has shown that S6K is involved in the development and progression of various types of cancer, including breast, lung, prostate, and colon cancer. Overexpression or hyperactivation of S6K has been observed in many cancer types.
Scientific Papers found: Click to Expand⟱
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
2979- CUR,  GB,    Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
- in-vitro, Lung, H157 - in-vitro, Lung, H1299
EGFR↓, Sp1/3/4↓, ERK↓, MEK↓, Akt↓, S6K↓,
445- CUR,    Curcumin Regulates the Progression of Colorectal Cancer via LncRNA NBR2/AMPK Pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
p‑AMPK↑, p‑ACC-α↑, NBR2↑, p‑S6K↓, mTOR↓,
959- PACs,    Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression
- in-vitro, GBM, U251 - in-vitro, BC, MDA-MB-231
Hif1a↓, p‑Akt↓, p‑S6K↓, p‑S6↓, VEGF↓,
1237- PTS,    Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
- in-vitro, Ovarian, SKOV3
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

MDA↑, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MEK↓, 2,   MMP↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

p‑ACC-α↑, 1,   AMPK↓, 1,   AMPK↑, 1,   p‑AMPK↑, 2,   FASN↓, 1,   Glycolysis↓, 1,   p‑S6↓, 1,   S6K↓, 1,   p‑S6K↓, 4,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 2,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Casp3↑, 2,   Casp9↑, 1,   p27↑, 1,   Telomerase↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,   p‑TSC2↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   NBR2↑, 1,   p‑P53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑4E-BP1↓, 1,   CD133↓, 1,   CSCs↓, 1,   Diff↓, 1,   EMT↓, 1,   ERK↓, 2,   mTOR↓, 1,   p‑mTOR↓, 1,   p‑mTORC1↓, 1,   n-MYC↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   PTEN↑, 1,   SOX2↓, 1,   STAT3↓, 1,  

Migration ⓘ

MMP2↓, 1,   MMP9↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,   Hif1a↓, 2,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

CCR7↓, 1,   COX2↓, 1,   CXCR4↓, 1,   IL6↓, 1,   Inflam↓, 1,   JAK2↓, 1,   MCP1↓, 1,   PGE2↓, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose?, 1,   Dose↓, 1,   Dose↑, 1,   eff↑, 3,   eff↝, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   IL6↓, 1,  
Total Targets: 78

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: S6K, S6 kinase
2 Curcumin
1 Berberine
1 gefitinib, erlotinib
1 Proanthocyanidins
1 Pterostilbene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:704  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page